Die Expression von c-erbB-2 und Topoisomerase IIα in Relation zur Zytostatikaresistenz beim Ovarialkarzinom

Zusammenfassung

In der vorliegenden Studie untersuchten wir die Rolle des c-erbB-2 für die Zytostatikaresistenz beim Ovarialkarzinom. Die Überexpression von c-erbB-2 mRNA im Tumorgewebe war mit einem kürzeren Überleben von Patientinnen mit primärem Ovarialkarzinom verbunden (p = 0,0001, n = 77) und ein unabhängiger prognostischer Faktor im Proportional Hazard Modell (p = 0,035). Eine signifikante Assoziation bestand zwischen der Expression von c-erbB-2 mRNA und Überleben in der Subgruppe der Patientinnen, die eine Standardchemotherapie mit Cisplatin/Carboplatin und Cyclophosphamid erhalten hatten (p = 0,0003). Darüber hinaus verbesserte die Applikation einer Standardchemotherapie das Überleben in der Subgruppe der Patientinnen mit geringer Expression von c-erbB-2 mRNA (p = 0,013), aber nicht in der Subgruppe der Patientinnen mit hoher Expression von c-erbB-2 mRNA (p = 0,359). Die Expression der c-erbB-2 mRNA korrelierte mit der Expression der mRNA von Topoisomerase IIα (p = 0,009), aber nicht mit der Expression der mRNA von Topoisomerase IIβ (p = 0,221). Die Bestimmungen erfolgten durch eine reverse semiquantitative PCR-Technik. Die Daten stützen die Hypothese, dass Topoisomerase IIα, das mit der Expression von c-erbB-2 korreliert, an der Entwicklung der Resistenz c-erbB-2-exprimierender Tumoren beteiligt ist.

Abstract

In the present study, we examined die role of c-erbB-2 for chemoresistance in ovarian cancer. Overexpression of c-erbB-2 mRNA in tumor tissue was associated with a shorter survival of patients with primary ovarian cancer (P = 0.0001, N = 77) and was an independent prognostic factor in the proportional-hazard model (P = 0.035). A significant association between expression of c-erbB-2 mRNA und survival was obtained for the subgroup of patients who received a standard chemotherapy with carboplatin or cisplatin and cyclophosphamide (P = 0.0003). In addition, the application of a standard chemotherapy improved the survival of patients with relatively low c-erbB-2 expression (P = 0.013), but not of patients with overexpression of c-erbB-2 (P = 0.359). Expression of c-erbB-2 mRNA correlated with expression of topoisomerase IIα mRNA determined by a reverse semiquantitative PCR technique (P = 0.009), whereas expression of c-erbB-2 und topoisomerase IIβ mRNA dit not correlate (P = 0.221). The data suggest that topoisomerase IIα, which correlates with c-erbB-2 expression, contributes to the resistance of c-erbB-2-overexpressing carcinomas.

Schlüsselwörter

c-erbB-2 - Topoisomerase IIα - Ovarialkarzinom - Zytostatikaresistenz

Key words

c-erbB-2 - Topoisomerase IIα - Chemoresistance - Ovarian cancer

Literatur

• 1 Ali-Osman F, Berger M S, Rajagonal S, Spence A, Livingston R B. Topoisomerase-II-inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells.  Cancer Res. 1993;  53 5663-5668
• 2 Bargmann C I, Hung M C, Weinberg R A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p183.  Cell. 1986;  45 649-657
• 3 Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper J G, Dodge R, Clarke-Pearson D L, Marks P, McKenzie S, Yin S, Bast R C. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.  Cancer Res. 1990;  50 4087-4091
• 4 Burt R K, Garfield S, Johnson K, Thorgeirsson S S. Transformation of rat liver epithelial cells with ν-H-ras or ν-raf causes expression of MDR-1, glutathione-S-transferase-π and increased resistance to cytotoxic chemicals.  Carcinogenesis [Br]. 1988;  9 2329-2332
• 5 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.  Anal Biochem. 1987;  162 156-159
• 6 Czernobilski B. Blaustein's Pathology of the Female Genital Tract. Springer, New York 1987; 560-607
• 7 De-Jong S, Timmer-Bosscha H, De-Vries E G, Multer N H. Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line.  Int J Cancer. 1993;  53 110-117
• 8 Di-Fiore P P, Pierce J H, Kraus M H, Segatto O, King C R, Aaronson S A. c-erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.  Science. 1987;  237 178-182
• 9 Eder J P , Chan V TW, Ng S-W, Rizvi N A, Zacharoulis S, Teicher B A, Schnipper L A. DNA topoisomerase IIα expression is associated with alkylating agent resistance.  Cancer Res. 1995;  55 6109-6116
• 10 Fan J, Banerjee D, Stambrook P J, Bertino J R. Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras.  Biochem Pharmacol. 1997;  53 1203-1209
• 11 Kalbfleisch J D, Prentice R C. The Statistical Analysis of Failure Data. Wiley, New York 1980
• 12 Hancock M C, Langton B C, Chan T, Toy P, Monahan J J, Mischak R P, Shawver L K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast an ovarian tumor cell lines.  Cancer Res. 1991;  51 4575-4580
• 13 Hashimoto S, Jing Y, Kawazoe N, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K. Bufalin reduces the level of topoisomerase II in human leukemia cell and affects the cytotoxicity of anticancer drugs.  Leuk Res. 1997;  21 875-883
• 14 Hengstler J G, Lange J, Kett A, Dornhöfer N, Meinert R, Arand M, Knapstein P G, Becker R, Oesch F, Tanner B. Contribution of c-erbB-2 and Topoisomerase IIα to chemoresistance in ovarian cancer.  Cancer Res. 1999;  59 3206-3214
• 15 Hudziak R M, Schlesinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH3T3 cells.  Proc Natl Acad Sci [Am]. 1987;  84 7159-7163
• 16 Keith W N, Douglas F, Wishart G C, McCallum H M, George W D, Kayxe S B, Brown R. Coamplification of erbB-2, topoisomerase IIα and retinoic acid receptorα genes in breast cancer and allelic loss at topoisomerase I on chromosome 20.  Eur J Cancer [Am]. 1993;  29 1469-1475
• 17 Kraus M H, Popescu N C, Amsbaugh S C, King C R. Overexpression of the EGF receptor-related proto-oncogen erbB-2 in human mammary tumor cell lines by different molecular mechanisms.  EMBO J. 1987;  6 605-610
• 18 Meden H, Marx C, Roegglen T, Schauer A, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer.  Int J Gynecol Pathol. 1998;  17 61-65
• 19 Pegram M D, Finn R S, Arzoo K, Beryt M, Pietras R J, Slamon D J. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.  Oncogene. 1997;  15 537-547
• 20 Pietras R J, Arboleda J, Reese D M, Wongvipat N, Pegram M D, Ramos L, Gorman C M, Parker M G, Slikowski M X, Slamon D J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.  Oncogene. 1995;  10 2435-2446
• 21 Reese D M, Slamon D J. HER-2/neu signal transduction in human breast and ovarian cancer.  Stem Cells. 1997;  15 1-8
• 22 Shih C, Padhy L C, Murray M, Weinberg R A. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts.  Nature [Br]. 1981;  290 261-264
• 23 Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.  Science [Am]. 1987;  235 177-182
• 24 Sklar M D, Prochownik E V. Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc.  Cancer Res. 1991;  51 2118-2123
• 25 Slamon D J, Godolphin W, Jones L A, Holt J A, Wong S G, Keith D E, Levin W J, Stuart S G, Udove J, Ullrich A, Press M F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.  Science [Am]. 1989;  244 707-712
• 26 Smith K A, Gorman P A, Stark M B, Groves R P, Stark G R. Distinctive chromosomal structures and formed very early in the amplification of CAD genes in Syrian hamster cells.  Cell. 1990;  63 1219-1227
• 27 Smith K, Houlbrook S, Greenall M, Carmichael J, Harris A L. Topoisomerase IIα co-amplification with c-erbB-2 in human breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.  Oncogene. 1993;  8 933-938
• 28 Tanner B, Kreutz E, Weikel W, Meinert R, Oesch F, Knapstein P G, Becker R. Prognostic significance of c-erbB-2 mRNA in ovarian carcinoma.  Gynecol Oncol. 1996;  62 268-277
• 29 Tanner B, Hengstler J G, Laubscher S, Meinert R, Oesch F, Weikel W, Knapstein P G, Becker R. Mdm 2 mRNA is associated with survival in ovarian cancer.  Int J Cancer. 1997;  74 438-442
• 30 Van-Waardenburg R C, Meijer C, Burger H, Nooter K, De-Vries E G, Mulder N H, De-Jong S. Effects of an inducible anti-sense c-myc gene transfer in a drug-resistane human small-cell-lung-carcinoma cell line.  Int J Cancer. 1997;  73 544-550
• 31 Venter D J, Tuzi N L, Kumar S, Gullick W J. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification.  Lancet. 1987;  2 69-72
• 32 Warenius H M, Seabra L A, Maw P. Sensitivity to cis-diamminedichloroplatinum in human small-cells is related to expression of cyclin D1 but not c-raf-1 protein.  Int J Acner. 1996;  67 224-231
• 33 Zhang L, Hung M C. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.  Oncogene. 1996;  12 571-576